Looking ahead to next year, we continue to expect high single-digit EPS growth in fiscal year 2027 driven by accelerating ...

Recent market growth is driven by advancements in understanding disease mechanics, targeted therapies like tolvaptan (Jynarque), and increased diagnosis rates. Tolvaptan, approved by the FDA, marks a ...